← SEC 公告列表 | CING SEC 公告 | Cingulate Inc.（CING）

業績公告 即時報告 8-K 2026-05-14

Cingulate Inc. 提交 8-K 表格，公佈截至 2026 年 3 月 31 日止季度（2026 年第一季）業績及業務更新

於 SEC 網站開啟原文

AI 繁中摘要

Cingulate Inc. 提交 8-K 表格，公佈截至 2026 年 3 月 31 日止季度（2026 年第一季）業績及業務更新 📄 公司於 2026 年 5 月 14 日發出一份新聞稿，內容涵蓋季度財務表現及最新業務進展。該新聞稿作為附件 99.1 一併提交，惟根據美國證券交易法規，此 8-K 及其附件僅屬「提供」性質，不視為「已提交」文件，亦不會自動納入其他申報中。 是次申報為 Item 2.02（營運與財務狀況結果），並無在 8-K 正文中披露具體財務數字。投資者如欲查閱完整業績，應參考隨附的新聞稿內容。 作為一家新興成長公司（Emerging Growth Company），Cingulate 仍處於專注臨床階段，其核心資產為注意力不足過動症（ADHD）相關候選藥物。市場將關注其研發進度、資金狀況及未來里程碑。投資者需留意 8-K 僅為初步通報，詳細分析應以公司後續發佈的季度報告（10-Q）為準。
展開英文正文 
false
 0001862150
 
 
 
 
 
 
 
 0001862150
 
 
 2026-05-14
 2026-05-14
 
 
 
 
 0001862150
 
 CING:CommonStockParValue0.0001PerShareMember
 
 
 
 2026-05-14
 2026-05-14
 
 
 
 
 0001862150
 
 CING:WarrantsExercisableForCommonStockMember
 
 
 
 2026-05-14
 2026-05-14
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

 

FORM
8-K

 

CURRENT
REPORT

Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date
of Report (Date of earliest event reported):

May
14, 2026

 

CINGULATE
INC.

(Exact
name of registrant as specified in its charter)

 

 
 Delaware
  
 001-40874
  
 86-3825535

 
 (State
 or other jurisdiction of

 incorporation)

  
 (Commission

 File
 Number)

  
 (IRS
 Employer

 Identification
 No.)

 
 

1901
W. 47th Place

Kansas
City, KS 66205

(Address
of principal executive offices) (Zip Code)

 

(913)
942-2300

(Registrant’s
telephone number, including area code)

 

 
 ___________________________________________________________________

 
 (Former
 name or former address, if changed since last report.)

 
 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):

 

 
 ☐
 Written communications
 pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
  
  

 
 ☐
 Soliciting material pursuant
 to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
  
  

 
 ☐
 Pre-commencement communications
 pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
  
  

 
 ☐
 Pre-commencement communications
 pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities
registered pursuant to Section 12(b) of the Act:

 

 
 Title
 of each class
  
 Trading
 Symbol(s)
  
 Name
 of exchange on which registered

 
 Common Stock, par value
 $0.0001 per share 
  
 CING
  
 The
 Nasdaq Stock Market LLC

 (Nasdaq
 Capital Market)

 
 Warrants, exercisable for
 common stock
  
 CINGW
  
 The
 Nasdaq Stock Market LLC

 (Nasdaq
 Capital Market)

 
 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging
growth company ☒

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

  

 

 

Item
2.02. Results of Operations and Financial Condition.

 

On
May 14, 2026, Cingulate Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026 and providing
a business update. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference. The information in this Item
2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item
9.01. Financial Statements and Exhibits.

 

(d)
Exhibits

 

 
 Exhibit
 No.
  
 Description

 
  
  
  

 
 99.1
  
 Press
 Release dated May 14, 2026

 
  
  
  

 
 104
  
 Cover Page Interactive
 Data File (embedded within the Inline XBRL document)

 
 

  

  

 

 

SIGNATURE

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

 

 
  
 CINGULATE INC.

 
  
  
  

 
 Dated: May 14, 2026
 By:
 /s/
 Jennifer L. Callahan

 
  
 Name:
 Jennifer L. Callahan

 
  
 Title:
 Chief Financial
 Officer